

Clinical correlation of gallstone disease in a Chinese population in Taiwan: Experience at Cheng Hsin General Hospital

Chi-Ming Liu, Tao-Hsin Tung, Pesus Chou, Victor Tze-Kai Chen, Chung-Te Hsu, Wu-Shyong Chien, Yeu-Tyng Lin, Hsu-Feng Lu, Hui-Chuan Shih, Jorn-Hon Liu

Chi-Ming Liu, Tao-Hsin Tung, Community Medicine Research Center & Institute of Public Health, National Yang-Ming University; Cheng Hsin General Hospital, Taipei, Taiwan, China Pesus Chou, Community Medicine Research Center & Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, China

Victor Tze-Kai Chen, Cardinal Tien Hospital; College of Medicine, Fu-Jen Catholic University; National Defence Medicine Center, Taipei, Taiwan, China

Chung-Te Hsu, Wu-Shyong Chien, Yeu-Tyng Lin, Hsu-Feng Lu, Cheng Hsin General Hospital, Taipei, Taiwan, China

Hui-Chuan Shih, Department of Nursing, Kaohsiung Military General Hospital, Kaohsiung, Taiwan, China

Jorn-Hon Liu, Faculty of Medicine, School of Medicine, National Yang-Ming University; Cheng Hsin General Hospital, Taipei, Taiwan, China

Co-first-author: Tao-Hsin Tung

Co-correspondents: Chi-Ming Liu

Correspondence to: Dr Jorn-Hon Liu, Cheng Hsin General Hospital, Shih-Pai, 112, Taipei, Taiwan, China. ch9043@chgh.org.tw Telephone: +886-2-28264400-8002 Fax: +886-2-28264550 Received: 2005-05-18 Accepted: 2005-08-26

Abstract

AIM: To explore the prevalence of gallstone disease (GSD) in Taiwan and condition-associated factors related to it.

METHODS: We studied a total of 2386 healthy adults (1235 males and 1151 females) voluntarily admitted to Cheng Hsin General Hospital for a paid physical check-up between January 2002 and December 2002. Blood samples and ultrasound sonography results were collected.

RESULTS: The overall prevalence of GSD among this study-population was 5.3%, including 1.7% (n = 40) having a single stone, 2.3% (n = 55) having multiple stones, and 1.3% (n = 31) having cholecystectomy. The prevalence revealed a statistically significant increase with increasing age (P < 0.0001). Females exhibited a greater prevalence of multiple stones than did males (3.0% *vs* 1.7%, P = 0.04). Using multiple logistic regression analysis, the following appeared to be significantly related to the prevalence of GSD: older age (40-49 years *vs* <40 years, OR = 1.63 [95% CI: 0.76-3.48], 50-59 years *vs* <40 years, OR = 4.93 [95%

CI: 2.43-9.99], 60-69 years vs < 40 years, OR = 6.82 [95% CI: 3.19-14.60], \geq 70 years vs < 40 years, OR = 10.65 [95% CI: 4.78-23.73]), higher BMI (\geq 27 kg/m² vs <24 kg/m², adjusted OR = 1.74 [95% CI: 1.04-2.88]), and higher FPG (\geq 126 mg/dL vs <110 mg/dL, OR = 1.71, 95%CI: 1.01-2.96).

CONCLUSION: Older age (\geq 50 years), obesity (BMI \geq 27 kg/m²), and type 2 diabetes (FPG \geq 126 mg/dL) are associated with the prevalence of GSD.

 \odot 2006 The WJG Press. All rights reserved.

Key words: Cross-sectional study; Gallstone disease; Prevalence; Risk factors

Liu CM, Tung TH, Chou P, Chen VTK, Hsu CT, Chien WS, Lin YT, Lu HF, Shih HC, Liu JH. Clinical correlation of gallstone disease in a Chinese population in Taiwan: Experience at Cheng Hsin General Hospital. *World J Gastroenterol* 2006; 12(8): 1281-1286

http://www.wjgnet.com/1007-9327/12/1281.asp

INTRODUCTION

Gallstone disease (GSD) is one of the most common diseases in developed countries. Recent studies indicate varying prevalence of GSD with several predisposing factors in different study populations^[1-9]. From a medical economic perspective, the direct and indirect costs of treating GSD patients were estimated at \$16 billion and account for more than 800000 hospitalizations yearly in the United States^[9,10]. In Taiwan, the prevalence of GSD in the general population was 4.3% in 1989^[8] while another voluntary screening revealed that the prevalence of GSD was 10.7% among healthy subjects in 1995^[2]. For this reason, due to westernization of the diet and the environment, GSD is not rare in the Chinese population and has become one of the major health problems in Taiwan^[7]. Without an appropriate and effective screening program for symptomatic GSD, the medical treatment of GSD and related complications contributes substantially to health care costs.

From the viewpoint of preventive medicine, it is

 Table 1 Prevalence of each type of gallstone disease among

 2386 Chinese subjects

Gallstone disease							
Variable	Total screened number	Single stone prevalence number (%)		Multiple stones prevalence number (%)		Cholecystectomy prevalence number (%)	
Gender							
Male	1235	21	(1.7)	21	(1.7)	17	(1.4)
Female	1151	19	(1.7)	34	(3.0)	14	(1.2)
<i>P</i> -value for χ^2 -test		0.95		0.04		0.76	
Age							
<40	745	4	(0.5)	5	(0.7)	2	(0.3)
40-49	723	6	(0.8)	7	(1.0)	6	(0.8)
50-59	504	11	(2.2)	21	(4.2)	8	(1.6)
60-69	252	7	(2.8)	17	(6.8)	6	(2.4)
70+	162	12	(7.4)	5	(3.1)	9	(5.6)
<i>P</i> -value for							
Cochran-Armi trend test	tage	<0	.0001	<0	.0001	<0	.0001
Total	2386	40	(1.7)	55	(2.3)	31	(1.3)

not only important to be cognizant of the background prevalence of GSD regionally, but also to explore the complete spectrum of demographic and biological markers which may be related to development of GSD. Although most epidemiologic studies of GSD, demographic factors and biochemical markers have used case-control designs and cross-sectional data^[1-9], to the best of our knowledge, some uncertainty still exists regarding the prevalence of the disease and the identity of the associated risk factors for the development of GSD. The present study was designed to explore potential associated risk factors and to improve understanding of the overall pathogenesis of GSD. The purpose of this study was to explore the context of associated risk factors for GSD prevalence amongst the general population aged 20 years or more, as determined by the application of a healthy volunteer subjects screening program at Cheng Hsin General Hospital, a fully certified regional hospital and teaching hospital in Taipei, Taiwan.

MATERIALS AND METHODS

Data resource and data collection

This cross-sectional study was conducted with a total of 2386 healthy adults (1235 males and 1151 females) voluntarily admitted to Cheng Hsin General Hospital for a paid physical check-up between January 2002 and December 2002. Blood samples and ultrasound sonography results were collected. Overnight-fasting blood samples were drawn via venipuncture from study participants by clinical nurses. Serum and plasma samples (from whole blood preserved with EDTA and NaF) were kept frozen (-20 °C) until ready for analysis. The study-used definition of type-2 diabetes was from the 1997 ADA criteria^[11]. Definitions of the following diseases / conditions were obesity: a body mass index (BMI) \geq 27 Kg/m², high systolic blood pressure (DBP) \geq 90 mmHg, hyper-

cholesterolemia ($\geq 200 \text{ mg/dL}$), hypertriglyceridemia ($\geq 200 \text{ mg/dL}$), low HDL (<35 mg/dL), high BUN ($\geq 20 \text{ mg/dL}$), high creatinine ($\geq 1.4 \text{ mg/dL}$), and hyperuricemia ($\geq 7 \text{ mg/dL}$ for males or $\geq 6 \text{ mg/dL}$ for females). Serum ALT or AST levels $\geq 40 \text{ U/L}$ were classified as elevated^[12]. In addition, information on HBV and anti-HCV were collected using radioimmunoassay kits.

Diagnosis of gallstone disease

In the present study, GSD was diagnosed by a panel of specialists using real-time ultrasound sonography (TOSHI-BA nemio SSA-550A, Japan) to examine the abdominal region after fasting for at least 8 h based on the presence of "movable hyper-echoic foci with acoustic shadow. Cases of GSD were classified as follows: single gallbladder stone, multiple gallbladder stones, and cholecystectomy, excluding gallbladder polyps. Cases were identified as any type of GSD study population.

Interobserver reliability in ultrasound sonography

In order to set up a consistent diagnosis of GSD between specialists, the Kappa statistic was used to assess the agreement of inter-observer reliability among study specialists. A pilot study was performed using 100 randomly selected healthy subjects other than the study participants. For inter-observer reliability, the Kappa value for diagnosis of GSD between specialists was 0.79 (95%CI: 0.61-0.95).

Statistical analysis

Statistical analysis was performed using SAS for Windows, (SAS version 9.0; SAS Institute Inc., Cary, NC, USA). A *P*-value of < 0.05 was considered statistically significant between two test populations. For univariate analysis, the two-sample, independent t-test method was adopted to assess differences in the mean value of continuous variables between subjects with and without GSD. Crude and adjusted odds ratios (adjustment for gender and age) were estimated and 95% confidence intervals were used. Multiple logistic regression was also performed in order to investigate the independence of risk factors associated with the prevalence of GSD.

RESULTS

The prevalence of each type of GSD amongst study subjects is presented in Table 1. The overall prevalence of GSD was 5.4%, including 1.7% (n=40) having a single stone, 2.3% (n=55) having multiple stones, and 1.3% (n=31) having cholecystectomy. Females (3.0%) had a significantly higher prevalence of multiple stones than males (1.7%) (P=0.04). There were no statistically significant differences in gender for other types of GSD. In addition, from the Cochran-Armitage trend test, the prevalence of each type of GSD showed an increase with age (P<0.0001). Subjects aged 50 years and over (96/918=10.5%) had a more than 5-fold risk for GSD compared with the subjects aged 50 years and less (30/1468=2.0%).

Figure 1 shows the gender- and age-specific prevalence of all types of GSD. Although there was no gender difference ($\chi^2 = 1.30$, P = 0.25) for the overall prevalence




Figure 1 Gender- and age-specific prevalence of all types of gallstone disease among 2386 Chinese subjects.



G;		ne diseas	e		
		No	Crude OR (95% CI)	Adjusted OR ¹ (95% CI)	
	(<i>n</i> =126)			(7570 CI)	
Gender male	59	1176	1.00	-	
female	67	1084	1.23 (0.86-1.76)		
Age (yr) <40	11	734	1.00	-	
40-49	19	704	1.80 (0.85-3.81)	-	
50-59	40	464	5.75 (2.92-11.32)		
60-69	30	222	9.02 (4.45-18.29)	-	
≥70	26	136	12.76 (6.16-26.43) -	
BMI (Kg/ m^2) <24	57	1343	1.00	1.00	
24-27	38	585	1.53 (1.00-2.33)	1.36 (0.88-2.10)	
≥27	31	332	2.20 (1.40-3.46)	2.04 (1.28-3.26)	
FPG (mg/dL) <110	93	2007	1.00	1.00	
110-12	5 10	122	1.77 (0.90-3.49)	1.14 (0.57-2.28)	
≥126	23	126	3.95 (2.42-6.45)	1.95 (1.16-3.30)	
High SBP No	93	1885	1.00	1.00	
Yes	33	375	1.78 (1.18-2.69)	1.18 (0.54-1.33)	
High DBP No	97	1801	1.00	1.00	
Yes	29	459	1.17 (0.77-1.80)	0.95 (0.61-1.48)	
Hypercholesterolemi	a No 93	1827	1.00	1.00	
	Yes 33	433	1.50 (1.00-2.26)	1.11 (0.72-1.69)	
Hypertriglyceridemi	a No 100	1946	1.00	1.00	
	Yes 26	314	1.61 (1.03-2.52)	1.54 (0.97-2.46)	
Low HDL No	122	2052	1.00	1.00	
Yes	4	208	0.32 (0.12-0.89)	0.62 (0.22-1.73)	
High BUN No	115	2118	1.00	1.00	
Yes	11	142	1.43 (0.75-2.71)	0.67 (0.34-1.33)	
High creatinine No	118	2214	1.00	1.00	
Yes	8	46	3.26 (1.51-7.07)	1.22 (0.54-2.78)	
Hyperuricemia No	43	963	1.00	1.00	
Yes	83	1297	1.43 (0.98-2.09)	1.18 (0.80-1.75)	
Higher AST No	106	2095	1.00	1.00	
Yes	20	165	2.40 (1.45-3.97)	1.96 (1.16-3.32)	
Higher ALT No	101	1883	1.00	1.00	
Yes	25	377	1.24 (0.79-1.94)	1.48 (0.92-2.37)	
HBV Negative	113	1975	1.00	1.00	
Positive	13	285	0.80 (0.44-1.43)	0.98 (0.54-1.78)	
Anti-HCV Negative	123	2204	1.00	1.00	
Positive	3	56	0.96 (0.30-3.11)	0.63 (0.19-2.07)	

¹Adjustment for gender and age.

	Any type of gallstone disease				
Variable	Yes	No	Total		
	(n = 126)	(n = 2260)	(<i>n</i> =2386)	<i>P</i> -value	
	Mean ± SD	Mean ± SD	Mean ± SD	for <i>t</i> test	
Age (yr)	58.63±13.04	46.57±13.22	47.21±13.48	< 0.0001	
BMI (kg/m²)	24.83 ± 3.64	23.50 ± 3.55	23.57 ± 3.57	< 0.0001	
FPG (mg/dL)	109.22±33.21	96.98 ± 25.21	97.63±25.84	< 0.0001	
SBP (mmHg)	130.06 ± 20.07	122.55 ± 18.40	122.94 ± 18.56	< 0.0001	
DBP (mmHg)	81.27 ± 12.22	79.56 ± 12.56	79.65±12.55	0.14	
Cholesterol (mg/dL)	216.93 ± 41.06	210.51 ± 37.72	210.87 ± 37.94	0.07	
Triglyceride (mg/dL)143.39±98.63	130.12 ± 108.06	130.86±107.58	8 0.18	
HDL (mg/dL)	57.02 ± 16.55	57.69 ± 15.76	57.65 ± 15.80	0.64	
BUN (mg/dL)	14.94 ± 6.28	13.55 ± 5.56	13.63 ± 5.61	0.02	
Creatinine (mg/dL)	1.08 ± 0.35	1.04 ± 0.40	1.04 ± 0.40	0.29	
Uric acid (mg/dL)	6.74±1.67	6.59 ± 1.72	6.60 ± 1.72	0.35	
AST (U/L)	32.79 ± 30.13	27.59 ± 17.59	27.88 ± 18.54	0.06	
ALT (U/L)	37.84 ± 54.27	30.01 ± 34.49	30.45 ± 35.91	0.11	

Table 2 Comparison of characteristics in subjects with and

without gallstone disease

of GSD, there was a statistically significant increase with increasing study-subject age by means of the trend test (z=9.66, P<0.0001). The prevalence of GSD also showed an interaction effect between gender and age, that is, males proved to have a substantially greater overall prevalence of GSD than females among those aged less than 50 years, whereas there was a lower overall prevalence of GSD among those aged more than 50 years.

The results of the comparison of a variety of test characteristics and their potential association with the prevalent GSD for study subjects are illustrated in Table 2. Using a two-sample independent *t*-test, the associated factors that were significantly related to GSD included age (yes $[58.63\pm13.04 \text{ years}] vs$ no $[46.57\pm13.22 \text{ years}]$), BMI (yes $[24.83\pm3.64 \text{ Kg/m}^2] vs$ no $[23.50\pm3.55 \text{ Kg/m}^2]$), fasting plasma glucose (FPG) (yes $[109.22\pm33.21 \text{ mg/dL}] vs$ no $[96.98\pm25.21\text{mg/dL}]$), SBP (yes $[130.06\pm20.07 \text{ mmHg}] vs$ no $[122.55\pm18.40 \text{ mmHg}]$), and BUN (yes $[14.94\pm6.28 \text{ mg/dL}] vs$ no $[13.55\pm5.56 \text{ mg/dL}]$).

Table 3 presents the crude and adjusted odds ratios for the association between certain relevant associated risk factors and the prevalence of GSD. Compared to individuals without GSD, in addition to older age (40 - 49 years vs <40 years, OR = 1.80 [95% CI: 0.85 - 3.81], 50-59 years vs <40 years, OR = 5.75 [95% CI: 2.92-11.32], 60-69 years vs <40 years, OR = 9.02 [95% CI: 4.45-18.29], \geq 70 years vs <40 years, OR = 12.76 [95% CI: 6.16-26.43]), subjects featuring GSD revealed a more-pronounced prevalence of: higher BMI (\geq 27 kg/m² vs <24 kg/m², adjusted OR = 2.04 [95% CI: 1.28-3.26]), higher FPG (\geq 126 mg/dL vs <110 mg/dL, OR = 1.95, 95% CI: 1.16-3.30), and higher AST (adjusted OR = 1.96, 95% CI: 1.16-3.32) subsequent to adjustment for gender and age.

The effect of independent associated risk factors on GSD was examined using a multiple logistic regression model. As depicted in Table 4, subsequent to adjustment for confounding factors, the following appeared to be significantly related to GSD prevalence: age (40-49 years vs < 40 years, OR = 1.63 [95% CI: 0.76-3.48], 50-59 years vs

 Table 4 Multiple logistic regression of associated factors for gallstone disease among 2386 Chinese subjects

VariableOR95%ClGender (female vs male)1.340.90-1.99Age (40-49 $vs < 40$ yr)1.630.76-3.48(50-59 $vs < 40$ yr)4.932.43-9.99(60-69 $vs < 40$ yr)6.823.19-14.60(≥ 70 $vs < 40$ yr)10.654.78-23.73BMI (24-27 $vs < 24$ kg/m²)1.250.79-1.97(≥ 27 $vs < 24$ kg/m²)1.741.04-2.88FPG (110-125 $vs < 110$ mg/dL)0.960.47-1.97(≥ 126 $vs < 110$ mg/dL)1.711.01-2.96High SBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)0.550.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31Higher ALT (yes vs no)0.830.42-1.63		Gallstone disease (yes <i>vs</i> no)	
Age (40-49 $vs < 40 yr$)1.630.76-3.48(50-59 $vs < 40 yr$)4.932.43-9.99(60-69 $vs < 40 yr$)6.823.19-14.60($\geq 70 vs < 40 yr$)10.654.78-23.73BMI (24-27 $vs < 24 kg/m^2$)1.250.79-1.97($\geq 27 vs < 24 kg/m^2$)1.741.04-2.88FPG (110-125 $vs < 110 mg/dL$)0.960.47-1.97($\geq 126 vs < 110 mg/dL$)1.711.01-2.96High SBP (yes vs no)1.110.53-1.51High DBP (yes vs no)0.870.52-1.48Hypertriglyceridemia (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)2.020.71-5.75Hyperuricemia (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	Variable	OR	95%CI
(50-59 $vs < 40 yr$)4.932.43-9.99(60-69 $vs < 40 yr$)6.823.19-14.60($\geq 70 vs < 40 yr$)10.654.78-23.73BMI (24-27 $vs < 24 kg/m^2$)1.250.79-1.97($\geq 27 vs < 24 kg/m^2$)1.741.04-2.88FPG (110-125 $vs < 110 mg/dL$)0.960.47-1.97($\geq 126 vs < 110 mg/dL$)1.711.01-2.96High SBP (yes vs no)1.110.53-1.51High DBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	Gender (female vs male)	1.34	0.90-1.99
(c) (1) (1) (1) (1) (1)(c) (1) (1) (1)(60-69 $vs < 40 yr$)6.823.19-14.60($\geq 70 vs < 40 yr$)10.654.78-23.73BMI (24-27 $vs < 24 kg/m^2$)1.250.79-1.97($\geq 27 vs < 24 kg/m^2$)1.741.04-2.88FPG (110-125 $vs < 110 mg/dL$)0.960.47-1.97($\geq 126 vs < 110 mg/dL$)1.711.01-2.96High SBP (yes vs no)1.110.53-1.51High DBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)2.020.71-5.75Hyperuricemia (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	Age (40-49 <i>vs</i> <40 yr)	1.63	0.76-3.48
(\geq 70 vs < 40 yr)10.654.78-23.73BMI (24-27 vs <24 kg/m²)	(50-59 <i>vs</i> <40 yr)	4.93	2.43-9.99
BMI (24-27 $vs < 24 \text{ kg/m}^2$)1.250.79-1.97 $(\geq 27 vs < 24 \text{ kg/m}^2)$ 1.741.04-2.88FPG (110-125 $vs < 110 \text{ mg/dL}$)0.960.47-1.97 $(\geq 126 vs < 110 \text{ mg/dL})$ 1.711.01-2.96High SBP (yes vs no)1.110.53-1.51High DBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	(60-69 <i>vs</i> <40 yr)	6.82	3.19-14.60
$(\ge 27 vs < 24 kg/m^2)$ 1.741.04-2.88FPG (110-125 vs <110 mg/dL)	(≥70 <i>vs</i> <40 yr)	10.65	4.78-23.73
FPG (110-125 vs <110 mg/dL) 0.96 $0.47-1.97$ $(\geq 126 vs <110 mg/dL)$ 1.71 $1.01-2.96$ High SBP (yes vs no) 1.11 $0.53-1.51$ High DBP (yes vs no) 0.87 $0.52-1.48$ Hypercholesterolemia (yes vs no) 0.99 $0.64-1.53$ Hypertriglyceridemia (yes vs no) 1.25 $0.75-2.08$ Low HDL (yes vs no) 0.55 $0.17-1.44$ High BUN (yes vs no) 0.59 $0.26-1.37$ High creatinine (yes vs no) 2.02 $0.71-5.75$ Hyperuricemia (yes vs no) 0.97 $0.64-1.46$ Higher AST (yes vs no) 2.06 $0.99-4.31$	BMI (24-27 <i>vs</i> <24 kg/m ²)	1.25	0.79-1.97
$(\geq 126 vs < 110 mg/dL)$ 1.711.01-2.96High SBP (yes vs no)1.110.53-1.51High DBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)1.250.75-2.08Low HDL (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)2.020.71-5.75Hyperuricemia (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	$(\geq 27 vs < 24 kg/m^2)$	1.74	1.04-2.88
High SBP (yes vs no)1.110.53-1.51High DBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)1.250.75-2.08Low HDL (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)2.020.71-5.75Hyperuricemia (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	FPG (110-125 vs <110 mg/dL)	0.96	0.47-1.97
High DBP (yes vs no)0.870.52-1.48Hypercholesterolemia (yes vs no)0.990.64-1.53Hypertriglyceridemia (yes vs no)1.250.75-2.08Low HDL (yes vs no)0.50.17-1.44High BUN (yes vs no)0.590.26-1.37High creatinine (yes vs no)2.020.71-5.75Hyperuricemia (yes vs no)0.970.64-1.46Higher AST (yes vs no)2.060.99-4.31	(≥126 vs <110 mg/dL)	1.71	1.01-2.96
Hypercholesterolemia (yes vs no) 0.99 0.64-1.53 Hypertriglyceridemia (yes vs no) 1.25 0.75-2.08 Low HDL (yes vs no) 0.5 0.17-1.44 High BUN (yes vs no) 0.59 0.26-1.37 High creatinine (yes vs no) 2.02 0.71-5.75 Hyperuricemia (yes vs no) 0.97 0.64-1.46 Higher AST (yes vs no) 2.06 0.99-4.31	High SBP (yes vs no)	1.11	0.53-1.51
Hypertriglyceridemia (yes vs no) 1.25 0.75-2.08 Low HDL (yes vs no) 0.5 0.17-1.44 High BUN (yes vs no) 0.59 0.26-1.37 High creatinine (yes vs no) 2.02 0.71-5.75 Hyperuricemia (yes vs no) 0.97 0.64-1.46 Higher AST (yes vs no) 2.06 0.99-4.31	High DBP (yes vs no)	0.87	0.52-1.48
Low HDL (yes vs no) 0.5 0.17-1.44 High BUN (yes vs no) 0.59 0.26-1.37 High creatinine (yes vs no) 2.02 0.71-5.75 Hyperuricemia (yes vs no) 0.97 0.64-1.46 Higher AST (yes vs no) 2.06 0.99-4.31	Hypercholesterolemia (yes vs no)	0.99	0.64-1.53
High BUN (yes vs no) 0.59 0.26-1.37 High creatinine (yes vs no) 2.02 0.71-5.75 Hyperuricemia (yes vs no) 0.97 0.64-1.46 Higher AST (yes vs no) 2.06 0.99-4.31	Hypertriglyceridemia (yes vs no)	1.25	0.75-2.08
High creatinine (yes vs no) 2.02 0.71-5.75 Hyperuricemia (yes vs no) 0.97 0.64-1.46 Higher AST (yes vs no) 2.06 0.99-4.31	Low HDL (yes vs no)	0.5	0.17-1.44
Hyperuricemia (yes vs no) 0.97 0.64-1.46 Higher AST (yes vs no) 2.06 0.99-4.31	High BUN (yes vs no)	0.59	0.26-1.37
Higher AST (yes vs no) 2.06 0.99-4.31	High creatinine (yes vs no)	2.02	0.71-5.75
	Hyperuricemia (yes vs no)	0.97	0.64-1.46
Higher ALT (yes <i>vs</i> no) 0.83 0.42-1.63	Higher AST (yes vs no)	2.06	0.99-4.31
	Higher ALT (yes vs no)	0.83	0.42-1.63
HBV (positive vs negative) 0.95 0.52-1.76	HBV (positive vs negative)	0.95	0.52-1.76
Anti-HCV (positive <i>vs</i> negative) 0.5 0.15-1.69	Anti-HCV (positive vs negative)	0.5	0.15-1.69

<40 years, OR = 4.93 [95%CI: 2.43 - 9.99], 60 - 69 years vs <40 years, OR = 6.82 [95% CI: 3.19 - 14.60], \geq 70 years vs <40 years, OR = 10.65 [95% CI: 4.78 - 23.73]), the higher BMI (\geq 27 kg/m² vs <24 kg/m², adjusted OR = 1.74 [95% CI: 1.04 - 2.88]), and higher FPG (\geq 126 mg/dL vs <110 mg/dL, OR = 1.71, 95% CI: 1.01 - 2.96).

DISCUSSION

Prevalence of gallstone disease in the general population

One of the important benefits of early screening for GSD is that ultrasonography can lead to the discovery of an increasing proportion of asymptomatic cases for which one can use therapeutic nonsurgical approaches, such as litholitic bile acids, local solvents, and lithotripsy^[13]. However, it appears that only a few published studies have attempted to determine the prevalence and possible etiology of GSD prevalence for the general population of Taiwan^[2,8,14], which also face a GSD burden. In the present study, GSD appeared to be fairly common for the test population, affecting an estimated 5.3% of the general population in Taiwan. The prevalence of GSD amongst different test populations appears to vary, differing among different studies conducted in different countries^[1,3-6]. In addition to different methods of GSD assessment, this disparity might be due to differences between different population stocks. The prevalence of GSD for our study population (5.3%) was lower than the corresponding figure presented in a previous hospital-based study conducted in the Veterans General Hospital (VGH), Taipei, Taiwan, which was reported to be 10.7%^[2]. The apparent lower prevalence rate in our study may have been due to younger age of the participants. Another possible reason for such

differences between the results of the VGH study and our results may simply have been related to the fact that although the kappa value for agreement of interobserver reliability seemed good ^[14], non-differential misclassification-bias identification could still be occurring and could lead to underestimation of GSD prevalence.

The implications of associated risk factors for gallstone disease

Our results reveal that older age represents a significant risk factor for GSD. Such a finding is consistent with results of other hospital-based and community-based studies conducted elsewhere^[2-5,7,8]. GSD is very seldom found in children, and in that age group is mainly associated with haemolytic causes^[15]. The long-term exposure to many other risk factors among elder persons may also account for the increased probability of developing GSD. Cholelithiasis is also an acquired disease contributed to by chronic environmental factors plus an aging effect^[7]. In addition, it has been suggested that among the elderly, larger amounts of cholesterol are secreted by the liver, and the catabolism of cholesterol to bile acid is decreased^[16,17].

Most previous epidemiologic studies have shown that females have a higher prevalence of GSD than males in the Western world. However, the male to female ratio seems to have changed from early reports, which showed figures of 1:4-6 to more recent studies where the ratio is 1:2 or less^[3,4,18]. Pregnancy and sex hormones could be involved by altering biliary secretion or gallbladder motility, or both may play an important role in sex-related differences in the prevalence of GSD^[13]. Another possible reason might be that estrogen replacement therapy or oral contraceptives are used^[19]. Our findings showed that, except for multiple stones, females do not have a significantly higher prevalence of all types of GSD than males. This result is similar to that from other hospital-based or populationbased studies conducted in Taiwan^[2,7,8].

After adjustment for confounding factors, the present study also suggests that obesity is highly correlated with GSD prevalence. Supersaturated bile is the linkage between obesity and cholesterol GSD. Obesity can raise the saturation of bile by increasing biliary secretion of cholesterol - the latter probably depending on a higher synthesis of cholesterol in obese subjects^[7,13,20]. While cholesterol GSD is common in Western countries, pigment GSD is still the principal component in Taiwan^[2]. Our results also implied that obesity may be an independent associated risk factor leading to prevalent pigment GSD in the Chinese population.

It has been a matter of controversy whether diabetes mellitus is associated with GSD or not^[7]. Consistent with previous studies^[4,7], our results showed that diabetes mellitus is highly associated with GSD prevalence. From a clinical perspective, hyperglycemia inhibits bile secretion from the liver and disturbs gallbladder contraction ^[2]. Supersaturated bile in the gallbladder induces cholelithiasis in diabetic subjects^[21]. The association of diabetics with GSD is stronger in subjects with a history of treated diabetes mellitus than in those with a simple history of diabetes and this could be an effect of hyperglycemia on gallbladder motility^[22]. Furthermore, diabetes mellitus combined with GSD may induce acute cholecystitis more frequently and have a higher possibility of progression to septicemia^[7].

An increasing prevalence of cholecystolithiasis has been associated with the etiology and severity of chronic liver disease and cirrhosis^[23]. Possible explanatory factors include overproduction and over-secretion of bilirubin due to increased extracorpuscular hemolysis, a reduction in the production and transportation of biliary salts and cholesterol secretion, stasis and changes in bile acidification, or even mucous hypersecretion and subtle alterations in gallbladder mucosal function^[24,25]. However, although early liver dysfunction such as abnormal ALT, HBV, and HCV infection are endemic in Taiwan^[12,26,27]. the present study did not reveal liver function associated factors to be related to GSD prevalence. This finding is consistent with other hospital-based studies for the general population in Taiwan^[2]. Further epidemiological and etiologic investigations are needed to clarify the pathophysiological mechanisms between early liver damage and pigment GSD among general Chinese populations.

Perceived limitations

A major limitation of the present study is the potential self-selection bias due to the hospital-based study design, that is, of it not being exactly representative of the whole general population. Second, it is well established that a large proportion of GSD patients remain asymptomatic and they are therefore often ignored for many years. Thus the present study may be representative of the clinical and not of the true prevalence. Thirdly, we do not detail to distinguish between cholesterol stones and pigment stones in this study, some measurement errors and different pathogenicity could occur. Fourthly, we did not consider how many individuals had progressive liver disease and explore the relationship between GSD and liver disease. Finally, our measurements were done only at a single time point and could not be able to be reflect long-term exposure to various demographic or biochemical aspects or factors, factors which might be important influencers of GSD. The solution to such a quandary is to conduct a number of prospective longitudinal analogous studies, the results of which would be expected to complement the cross-sectional findings of this study.

CONCLUSION

In conclusion, older age, obesity (BMI \ge 27 kg/m²), and type 2 diabetes (FPG \ge 126 mg/dL) are associated with GSD prevalence. Further studies are needed not only to elucidate the temporal sequence of events that typically lead to GSD, but also to further explore the pathogenesis of GSD in the general Chinese population.

REFERENCES

- Diehl AK, Schwesinger WH, Holleman DR Jr, Chapman JB, Kurtin WE. Clinical correlates of gallstone composition: distinguishing pigment from cholesterol stones. *Am J Gastroenterol* 1995; 90: 967-972
- 2 Chen CY, Lu CL, Huang YS, Tam TN, Chao Y, Chang FY, Lee

SD. Age is one of the risk factors in developing gallstone disease in Taiwan. *Age Ageing* 1998; **27**: 437-441

- 3 Lirussi F, Nassuato G, Passera D, Toso S, Zalunardo B, Monica F, Virgilio C, Frasson F, Okolicsanyi L. Gallstone disease in an elderly population: the Silea study. *Eur J Gastroenterol Hepatol* 1999; 11: 485-491
- 4 De Santis A, Attili AF, Ginanni Corradini S, Scafato E, Cantagalli A, De Luca C, Pinto G, Lisi D, Capocaccia L. Gallstones and diabetes: a case-control study in a free-living population sample. *Hepatology* 1997; 25: 787-790
- 5 Kono S, Shinchi K, Todoroki I, Honjo S, Sakurai Y, Wakabayashi K, Imanishi K, Nishikawa H, Ogawa S, Katsurada M. Gallstone disease among Japanese men in relation to obesity, glucose intolerance, exercise, alcohol use, and smoking. *Scand J Gastroenterol* 1995; **30**: 372-376
- 6 Sasazuki S, Kono S, Todoroki I, Honjo S, Sakurai Y, Wakabayashi K, Nishiwaki M, Hamada H, Nishikawa H, Koga H, Ogawa S, Nakagawa K. Impaired glucose tolerance, diabetes mellitus, and gallstone disease: an extended study of male self-defense officials in Japan. Eur J Epidemiol 1999; 15: 245-251
- 7 Liu CM, Tung TH, Liu JH, Lee WL, Chou P. A communitybased epidemiologic study on gallstone disease among type 2 diabetics in Kinmen, Taiwan. *Dig Dis* 2004; 22: 87-91
- 8 Lu SN, Chang WY, Wang LY, Hsieh MY, Chuang WL, Chen SC, Su WP, Tai TY, Wu MM, Chen CJ. Risk factors for gallstones among Chinese in Taiwan. A community sonographic survey. J Clin Gastroenterol 1990; 12: 542-546
- 9 Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. *Gastroenterology* 1999; **117**: 632-639
- 10 Zacks SL, Sandler RS, Rutledge R, Brown RS Jr. A populationbased cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. *Am J Gastroenterol* 2002; 97: 334-340
- 11 American Diabetes Association: clinical practice recommendations 1999. Diabetes Care 1999; 22 Suppl 1: S1-114
- 12 Wang CS, Wang ST, Chang TT, Yao WJ, Chou P. Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression. *Arch Intern Med* 2002; **162**: 811-815
- 13 Sama C, Labate AM, Taroni F, Barbara L. Epidemiology and natural history of gallstone disease. *Semin Liver Dis* 1990; 10: 149-158
- 14 Byrt T. How good is that agreement? Epidemiology 1996; 7: 561
- 15 **Soloway RD**, Trotman BW, Ostrow JD. Pigment gallstones. *Gastroenterology* 1977; **72**: 167-182
- 16 Einarsson K. Why do humans secrete too much of cholesterol into their bile? *Hepatol Rap Lit Rev* 1992; 22: 11
- 17 Méndez-Sánchez N, Cárdenas-Vázquez R, Ponciano-Rodríguez G, Uribe M. Pathophysiology of cholesterol gallstone disease. Arch Med Res 1996; 27: 433-441
- 18 Bainton D, Davies GT, Evans KT, Gravelle IH. Gallbladder disease. Prevalence in a South Wales industrial town. N Engl J Med 1976; 294: 1147-1149
- 19 Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg 1993; 165: 399-404
- 20 Bouchier IAD. Gallstones: Formation and epidemiology; in Blumgart LH (ed): Surgery of the Liver and Biliary Tract. Edinburgh, Churchill Livingstone, 1998, pp 503-516
- 21 **de Leon MP**, Ferenderes R, Carulli N. Bile lipid composition and bile acid pool size in diabetes. *Am J Dig Dis* 1978; **23**: 710-716
- 22 Misciagna G, Leoci C, Guerra V, Chiloiro M, Elba S, Petruzzi J, Mossa A, Noviello MR, Coviello A, Minutolo MC, Mangini V, Messa C, Cavallini A, De Michele G, Giorgio I. Epidemiology of cholelithiasis in southern Italy. Part II: Risk factors. Eur J Gastroenterol Hepatol 1996; 8: 585-593
- 23 Del Olmo JA, García F, Serra MA, Maldonado L, Rodrigo JM. Prevalence and incidence of gallstones in liver cirrhosis. *Scand J Gastroenterol* 1997; 32: 1061-1065
- 24 Alvaro D, Angelico M, Gandin C, Ginanni Corradini S, Capocaccia L. Physico-chemical factors predisposing to pigment gallstone formation in liver cirrhosis. J Hepatol 1990; 10: 228-234

- 25 Jacyna MR. Interactions between gall bladder bile and mucosa; relevance to gall stone formation. *Gut* 1990; **31**: 568-570
- 26 Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. *Am J Trop Med Hyg* 2002; 66:

389-393

27 Liu CM, Tung TH, Liu JH, Chen VT, Lin CH, Hsu CT, Chou P. A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World J Gastroenterol 2005; 11: 1616-1622

S- Editor Wang J L- Editor Guo SY E- Editor Liu WF